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Summary 
T cell colonies were generated from the peripheral blood mononudear cells (PBMC) of 10 patients 
with  tropical  spastic  paraparesis/human  T  lymphocyte  virus  type  I  (HTLV-I)-associated 
myeloencephalopathy (TSP/HAM),  two  healthy HTLV-I  carriers,  and  17  healthy HTLV-I- 
seronegative subjects.  PBMC were cultured in methylcellulose in the absence of added growth 
factors (spontaneous T cell colonies), or in the presence of phorbol myristate acetate and interleukin 
2 (induced T  cell colonies). PBMC T  cell colony-forming cells (T-CFC) from all TSP/HAM 
patients and HTLV-I carriers were able to grow in the absence of added growth factors and/or 
mitogenic stimulation. Pooled spontaneous and induced colonies were composed of cells bearing 
CD3 +,  CD4 +,  CD8 +,  and  CD1 +  antigens.  Colonies  from  normal  HTLV-I-seronegative 
subjects displayed mature cells bearing the CD3 + , CD4 + , CD8 + , and CD1-  surface phenotype. 
In addition,  spontaneous and induced T  cell colonies expressed HTLV-I antigens in 18-38% 
of the cells from TSP/HAM patients and HTLV-I carriers. These results demonstrate that HTLV-I 
infection is associated  with an abnormal proliferation and differentiation of T  cell progenitors 
in vitro and that the T-CFC from HTLV-I-seropositive individuals are infected, suggesting that 
T-CFC abnormalities may play a predominant role in the pathophysiology of HTLV-I. 
number of assays have been developed in semisolid media 
to detect T cell colony-forming cells (T-CFC). 1 These 
T-CFC have been used to determine the number of T  cell 
progenitors and to study the differentiation capacity of pe- 
ripheral blood and bone marrow T  lymphocytes in normal 
subjects and in patients with a variety of pathological condi- 
tions  (1-8).  In AIDS, results with the T-CFC assays have 
demonstrated that the T-CFC are infected with HIV-1  and 
that abnormalities in proliferation and differentiation were 
associated with a worse prognosis, suggesting a relation with 
disease  progression (9-14). 
Growth of blood and bone marrow T cell colonies from 
healthy individuals requires stimulation with PHA and II,-2; 
these colonies are called induced, in contrast to spontaneous 
T cell colonies, which grow without PHA and IL-2. Sponta- 
neous T cell colonies are not observed in normal circumstances. 
1 Abbreviations used in thispaper: A, adherent; ce-MEM, ce-modified Eagle's 
medium; IFA, indirect immunofluorescence assay; T-CFC, T cell colony- 
forming cells; TSP/HAM, tropical spastic paraparesis/HTLV-l-associated 
myeloencephalopathy. 
Induced colonies from healthy individuals are comprised of 
mature T  cells with mainly a CD3 +  CD4 + surface pheno- 
type. However, some CD3 +  CD8 + cells have also been de- 
tected in the colonies of these T cell progenitors (9-13). T-CFC 
have  either  an  immature  (CD2-CD3-)  phenotype  (dis- 
playing neither receptors for sheep erythrocytes, nor CD3 
membrane antigens), or more frequently a presumably ma- 
ture (CD2 +  CD3 +) presentation (9-13). CD1 + cells are not 
observed among the progeny of T-CFC in normal individ- 
uals (9).  On the other hand,  CD1 + cells are found in the 
colonies of T cell progenitors in vitro (9-13) and in the pe- 
ripheral blood in vivo of patients with AIDS (our unpub- 
lished data). 
HTLV-I is a type C human retrovirus (15, 16) etiologically 
linked with adult T  cell leukemia/lymphoma (17),  a lym- 
phoproliferative malignancy characterized by a clonal expan- 
sion of CD4* lymphocytes and by a monodonal integration 
of the provirus(es) in the tumor cells (18, 19). The presence 
of specific  antibodies  in  serum and cerebrospinal fluid of 
patients  has  also  linked HTLV-I with  a chronic myeloen- 
cephalopathy,  called  tropical  spastic  paraparesis/HTLV-I- 
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taneous proliferation of PBMC from patients with TSP/HAM 
and from healthy HTLV-I-infected carriers has been reported 
(25-30). The reverse transcriptase PCR has also shown HTLV-I 
transcripts  in  the  PBMC  from  patients  with  TSP/HAM 
(29-32).  Whether and at what level spontaneous lympho- 
cyte proliferation and HTLV-I expression are related to each 
other remain to be determined. 
The present study demonstrates for the first time that spon- 
taneous T  cell colonies can be generated from PBMC of all 
TSP/HAM patients and asymptomatic HTLV-I carriers ex- 
amined. Furthermore, induced and/or spontaneous colonies 
were composed of CDI+,  CD4 +,  and  CD8 +  cells,  indi- 
cating an abnormal in vitro T-CFC differentiation. In addi- 
tion,  18-38% of these T  cell colonies express HTLV-I viral 
antigens, and HTLV-I virus could easily be isolated from these 
cells. 
These results support the conclusion that HTLV-I infec- 
tion is associated with an abnormal proliferation and differen- 
tiation of T cell progenitors in vitro, as evidenced by the spon- 
taneous T  cell colony growth and the CD1 + cells in the T 
cell colonies. Furthermore, the T-CFC from HTLV-I carriers 
and TSP/HAM patients are infected, raising the possibility 
that the T-CFC may be an important reservoir or target for 
infection in vivo, in contrast to the assumption that the ma- 
ture CD4 + T  cells are the chief HTLV-I targets, because the 
leukemias  due  to HTLV-I almost  always involve CD4 +  T 
cells. 
Materials and Methods 
Patients.  Heparinized peripheral blood was obtained from 10 
patients with TSP/HAM, two healthy HTLV-I-seropositive  car- 
riers, and 17 HTLV-I- and HIV-l-seronegative donors. All patients 
fulfilled the TSP/HAM criteria (20-23, 31,  32). 
Cell Separation.  PBMC were separated on Ficoll-Paque (Phar- 
macia Fine Chemicals,  Uppsala,  Sweden).  Interphase cells were 
washed twice with PBS (Advanced Biotechnologies, Inc., [ABI], 
Columbia, MD) and resuspended in growth medium (~-modified 
Eagle's medium  [c~-MEM]; GIBCO BRL, Gaithersburg, MD). 
Their viability, as tested by trypan blue dye exclusion, was always 
>90%. In some experiments, cells were further separated on the 
basis  of  rosette  formation  with  2-amino-ethylisothiouronium 
hydrobromide (AET; Sigma Molecular Bio, St. Louis, MO)-treated 
SRBC (ABI) (33) and a second Ficoll-Paque density-gradient cen- 
trifugation. Thereafter, interphase cells were treated with anti-CD3 
mAb (Ortho, Raritan, NJ) (50/zl/106 cells in a final dilution of 
1:400; vol/vol) at 4~  followed by rabbit complement (70-90 
/~1/106 cells in a final dilution of 1:8; vol/vol) (Cedarlane Labora- 
tories, Hornby, Ontario) at 37~  This cell fraction contained <2% 
of CD2 + and CD3 § cells and will be referred to as E-CD3- cells. 
The phenotypic characterization of E-CD3-  cells showed  1% 
CD3 + cells, 1% CD2 § cells, 0% CD1 + cells, 1% CD20 + cells, 
0% CD56 + cells, 5-8% CD34 + cells, and 35-40% CD71* cells. 
Staining of the E-CD3-  cells with fluorescein-conjugated goat 
anti-mouse antibody did not reveal any positive cells, demonstrating 
that the CD3 determination on E-CD3-  cells was not blocked 
by the anti-CD3 mAb that was used to deplete T  cells. E + cells 
were obtained from the pellet of the second density centrifugation 
after hypotonic lysis of the SRBC. Their viability, as tested by trypan 
blue dye e~xlusion, was >90%. Adherent (A §  and nonadherent 
(A-)  PBMC were obtained after cell adherence to plastic  petri 
dishes:  PBMC  (106 cells/ml)  were incubated  in  oe-MEM  sup- 
plemented with 10% (vol/vol) FCS and 2 mM glutamine for 2 h 
in an incubator gassed with 5% COz at 37~  The nonadherent 
cells (A-) were collected, centrifuged, and stained for naphthyl es- 
terase. They always revealed <5% positive cells. Adherent cells were 
obtained by extensive  vigorous washing of the dishes. 
T  Cell Colony Assay.  Fractionated or unfractionated PBMC 
(5  x  106 cells/ml) were seeded in 0.8%  methylcellulose (Fluka 
Chemie AG, Buchs, Switzerland) in c~-MEM supplemented with 
20% FCS, 2 mM glutamine, and antibiotics in the presence (in- 
duced T cell colonies) of PHA (1%; vol/vol) and 10 U/nil of human 
rib2 (Biogen, Geneva, Switzerland), in the absence of PHA and 
rlL-2 (spontaneous T  cell colonies),  and in the presence of rib2 
without PHA.  In some experiments, 5  x  10  s cells/ml were in- 
cubated for 1 h  at 4~  or 37~  with  10-20 gg/ml of anti-Tac 
(Coulter Immunology, Hialeah, FL), anti-p75 (Mik/5 1; Endogen, 
Inc., Boston, MA) or both anti-Tac (CD25) and anti-p75 mAbs, 
which recognize the I1r  c~ (CD25) and p75 B chains,  respec- 
tively. The cells were washed extensively and seeded in methylcel- 
lulose in the presence or absence of growth factors.  In addition, 
unfractionated PBMC,  A-,  E +,  A-E +,  and  A-E-CD3-  cells 
(5  x  106 cells/ml) were incubated for 1 h at 4~  or 37~  with 
10-20 #g/ml of anti-CD3, anti-MHC class I, and class II mAb 
(Amac, Inc., Westbrook, ME). Cells were washed extensively and 
seeded in methylcellulose in the absence of growth factors. Also, 
unfractionated PBMC,  A-,  A-E +,  E +,  and  A-E-CD3-  cells 
(5  x  106 cells/ml) were cultured with different concentrations of 
autologous adherent cells or adherent cells from allogeneic healthy 
donors (2  x  10  s, 5  x  106, and 1  x  106 cell/ml) and seeded in 
methylcellulose without growth factor. 0.1 ml of cell-containing 
methylcellulose preparation was  seeded per well in 96-well  flat- 
bottomed microtest plates and incubated at 37~  in 5% COs in 
air for 5-7 d. Aggregates containing at least 50 cells were counted 
under an inverted microscope as colonies.  Colonies of the same 
morphology and size were picked up individually and pooled. The 
cells were dissociated, washed, and immunophenotyped as described 
below. 
Self-Renewal Capacity.  The clonogenic capacity of T-CFC was 
studied by two culture procedures.  First,  PBMC  (106 cells/ml) 
were incubated in growth medium supplemented with 10% FCS 
and 2 mM glutamine for 4 d at 37~  in 5% COs in air. 5  x  10  s 
washed viable cells/ml were seeded in methylcellulose as described 
above (delayed plating). The second method was to pick individual 
primary spontaneous colonies, and pool and dissociate them by pipet- 
ting. After washing,  5  x  10  s viable eells/ml were seeded as for 
primary colony growth in the absence or in the presence of added 
growth factors. 
Phenotypic Studies and Expression of Viral Proteins.  Cell pheno- 
type was determined by indirect immunofluorescence assays (IFA) 
using a panel of mAbs against the CD1, CD3, CD4, CD8 (Ortho 
Diagnostic  Systems,  Raritan,  NJ),  and CD25  (Coulter Immu- 
nology) molecules.  Moreover,  IFA  was  also  used to detect the 
expression of HTLV-I proteins with a gag p19 mAb, an anti-Tax1 
antiserum, and polyclonal sera from TSP/HAM patients. FITC- 
coupled goat anti-mouse or anti-human IgG antibodies (Nordic 
Immunology, Tilburg, The Netherlands) were used as a second 
reagent. The cells were examined using an epifluorescence micro- 
scope (E. Leitz, Inc., Rockleigh, NJ). 
Cell Infection.  In some experiments, pooled colony (spontaneous 
or induced) cells were irradiated with 2,500 cGy and cocultured 
with cord blood mononuclear cells in KPMI 1640 supplemented 
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were tested for the expression of gag p19 and CD1 antigens. Fur- 
thermore, two-color immunofluorescence studies were performed 
as reported (34) using mAb coupled to rhodamine and fluorescein. 
Electron Microscopy.  Samples  were taken from T cell colonies 
after 3, 6, and 9 d of culture, fixed in 1.25% glutaraldehyde and 
0.1 M  sodium cacodylate in 0.5 M PBS, and stained with  1% 
aqueous uranyl acetate. After dehydration, the samples were em- 
bedded in epoxy resin. Ultrathin sections of samples were exam- 
ined using an electron microscope (Hitachi). 
Statistical Analysis.  Statistical comparison of the mean values 
for T ceU colony growth of different fractions and growth condi- 
tions was performed using Fisher's analysis of variance, with 95% 
confidence limits. 
Results 
PBMC Phenotype.  The phenotypic characterization of pri- 
mary, uncultured PBMC from TSP/HAM patients showed 
58-78% CD3 + cells, 48-56% CD4 + cells, 16-30% CD8 + 
cells, 0% CD1 + cells, and 0% HTLV-I gag p19 + cells (Table 
1). The expression of CD25 was increased (9-28%) in PBMC 
of  both TSP/HAM patients and healthy HTLV-I carriers, in- 
dicating that T  cells are already activated in vivo as known 
from earlier studies (see Discussion). 
T Cell Colony Formation.  Not only induced, but also spon- 
taneous, T cell colonies were grown from the PBMC of all 
TSP/HAM patients and healthy HTLV-I carriers. In contrast, 
only induced T-CFC could be generated from the PBMC of 
HTLV-I-seronegative controls (Tables 2 and 3). In the pres- 
ence of 10 U/ml of rIL-2,  and without additional PHA or 
mitogen stimulation, the growth of T-CFC was significantly 
inhibited as compared with the spontaneous colony forma- 
tion in all cases of TSP/HAM patients and healthy HTLV-I 
carriers (Table  3). 
Table 2.  Induced PBMC T  Cell Colony 
Growth in TSP/HAM Patients, HTLV-I Carriers, 
and HTLV-I-seronegative Controls 
Patients  Diagnosis  PBMC T-CFC 
1  TSP/HAM  220  +_  20 
2  TSP/HAM  298  _+  12 
3  TSP/HAM  262  _+  26 
4  TSP/HAM  332  _+  28 
5  TSP/HAM  421  +  23 
6  TSP/HAM  380  _+  10 
7  TSP/HAM  244  +  45 
8  TSP/HAM  245  _+  17 
9  TSP/HAM  303  +  47 
10  TSP/HAM  377  +_  33 
11  Carrier*  310  _+  12 
12  Carrier*  351  +  11 
HTLV-I seronegatives 
(n  =  17)  370  _+  179 
Results are expressed as the mean number of colonies _+ SD per 5  x 
104 seeded cells from triplicate cultures. 
* Healthy HTLV-I carriers. 
To determine whether  the interaction of Ib2  with  its 
receptor (Ib2R) is involved in the spontaneous colony growth, 
cultures were tested after incubating PBMC with anti-Tac 
or anti-p75 mAbs  alone or with both mAbs together. As 
shown in Fig.  1, spontaneous T cell colony formation could 
strongly be inhibited after the treatment with the anti-Tac 
Table  1.  Immunological Characteristics of HTLV-I-infected Individuals 
Patients  Diagnosis  p19  CD1 
Percent positive PBMC 
CD25  CD3  CD4  CD8 
1  TSP/HAM  0  0 
2  TSP/HAM  0  0 
3  TSP/HAM  0  0 
4  TSP/HAM  0  0 
5  TSP/HAM  0  0 
6  TSP/HAM  0  0 
7  TSP/HAM  0  0 
8  TSP/HAM  0  0 
9  TSP/HAM  0  0 
10  TSP/HAM  0  0 
11  Carrier*  0  0 
12  Carrier*  0  0 
20  75  56  30 
17  78  58  28 
21  ND  ND  ND 
18  69  54  29 
15  71  55  21 
19  62  52  18 
22  72  63  19 
19  ND  ND  ND 
28  61  48  18 
26  74  49  23 
22  58  50  16 
9  ND  ND  ND 
" Healthy HTLV-I carriers. 
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Patients  Spontaneous  rlL-2 
1  35  _+  5  12  +_  3 
2  52  _+  7  14  _+ 2 
3  85  +_  7  51  _+  5 
4  45  _+  5  17  _+  3 
5  57  _+  4  15  _+  9 
6  45  _+  7  23  +_  6 
7  40  _+  2  28  _+  3 
8  111  _+  9  58  _+  12 
9  29  _+  2  20  _+  4 
10  96  _+  6  78  +_  7 
11"  20  _+  2  15  _+  7 
12"  96  +_  14  46  +_  6 
13  seronegative 
HTLV-I controls (n  =  5)  0  0 
Results are expressed as mean _+ SD of colonies per 5 x  104 seeded cells 
from triplicate cultures. 
" Healthy HTLV-I carriers. 
and anti-p75 mAbs. These IL-2R antibodies inhibited the spon- 
taneous T  cell colony growth formation of PBMC from the 
three TSP/HAM patients and the one healthy HTLV-I car- 
rier  tested. 
To determine more precisely the nature of the clonogenic 
T-CFC,  such  as  mature  (E*  CD3 +)  and  immature  (E- 
CD3-)  T-CFC,  the  following PBMC  fractions  were  also 
tested  for  T  cell  colony  growth;  E +,  adherent  negative 
(A-), A- E +, E- CD3-,  A- E- CD3-,  and A +.  As shown 
in Table 4, PBMC with (E + and A-E +) or without T  cell 
markers (E-CD3-  and A-E-CD3-)  were able to generate 
spontaneous colonies, demonstrating that spontaneous T cell 
colonies originated from both mature and immature T-CFC. 
A-,  E +,  or  A-E +  cell  fractions  generated  a  significantly 
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Figure  1.  Inhibition of spontaneous T cell colony  formation  with mAbs 
directed against the Tac p55(CD25) and/or p75 chains of IL-2R. Results 
are expressed as in Table 2 (or, anti-). 
lower number of spontaneous T cell colonies than unfractio- 
hated PBMC (Scheffe F  test, p  =  0.0018),  suggesting that 
adherent cells are needed for spontaneous T  cell colony for- 
mation. The differences were less marked for the immature 
T-CFC  (A-E-CD3-  or  E-CD3-).  Adherent  cells  (A § 
from TSP/HAM patients  did not  generate  spontaneous T 
cell colonies.  Moreover,  spontaneous T  cell colony forma- 
tion from A- cells could be restored by the addition of au- 
tologous but not aUogeneic A + cells  (Fig. 2). This suggests 
that  A +  cells  are required  to generate  spontaneous  T  cell 
colonies from mature T-CFC. As shown in Fig. 3, sponta- 
neous T  cell colony formation from unfractionated PBMC, 
A-E +,  and  A-E-CD3-  cells  could  not  be  inhibited  or 
stimulated after treatment with anti-CD3, or anti-MHC class 
I or II mAbs. In addition, the number of spontaneous T  cell 
colonies from all fractions examined was not affected by the 
addition  of aUogeneic adherent  cells. 
Phenotypic Characterization of T Cell Colonies.  Induced as 
well as spontaneous T  cell colonies generated from PBMC 
from TSP/HAM patients and HTLV-I carriers were composed 
of activated T  cells,  with Tac (CD25) antigens on their sur- 
face membrane (Table 5).  In addition,  18-38%  of the cells 
expressed  HTLV-I antigens,  as demonstrated by IFA using 
Table  4,  Spontaneous Colony Formation from Different Cell Fractions of TSP/HAM Patients' and Healthy Carrier's PBMC 
Unfractionated 
Patient  PBMC  A-  E +  E - CD3 -  A - E +  A - E - CD3 -  A + 
2  110  +_  12  7  +_  4  6  -+  2  55  -+  6  3  -+  1  70  +_  11  0 
10  96  +-  6  6  -+  1  20  +  2  74  +  8  6  +  2  42  +  7  0 
13  76  +  5  11  -+  4  43  _+  5  112  +  16  45  +  4  83  _+  5  0 
5  82  +  3  11  +  3  10  _+  1  72  +-  6  11  _+  4  74  _+  7  0 
11"  124  +  8  17  +_  5  12  _+  2  93  +_  8  24  +  5  98  _+  5  0 
Results are expressed as mean number of colonies _+ SD per 5  x  104 seeded cells from triplicate cultures. 
* HTLV-I carrier. 
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Figure 2.  Effect  of A + (autologous or allogeneic adherent cells) on 
spontaneous T cell colony formation from TSP/HAM patients and HTLV-I 
carder. Results are expressed as in Fig. 1. 
a gag p19 mAb (Table 5), and polyclonal sera from TSP/HAM 
patients (data not shown). In addition, 28-34% of the cells 
displayed a CD1 + phenotype, as determined by IFA, indi- 
cating an aberrant in vitro differentiation of the T-CFC. Not 
more than 4% CD1 + cells were observed in T cell colonies 
induced from PBMC T-CFC of healthy seronegative indi- 
viduals. The cells expressing viral antigens seem to be T cells 
with abnormal in vitro differentiation. Indeed, two-color im- 
munofluorescence  revealed  that  19-30%  of CD1 +  cells, 
5-8%  of CD4 + cells,  and 5-7%  of CD8 + cells were also 
stained by the HTLV-I gag p19 antibody. In addition, spon- 
taneous T  cell colonies generated from E-CD3-  ceils from 
TSP/HAM  patients  were composed of cells  with  similar 
phenotypic  features:  71-79%  were  CD3 +  cells,  59-64% 
CD4 +, 26-31% CDI*,  21-27% CD8 + , 24-34% CD25 + , 
and 33-50% HTLV-I gag p19 (Table 5). Electron microscopy 
revealed retroviral particles, indistinguishable from HTLV-I, 
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Figure 3.  Effect of allogeneic adherent cells, 
anti-CD3,  anti-MHC class I, and MHC class II 
mAbs on spontaneous  T cell  colony  formation from 
unfractionated PBMC, A-E  +  , and A-E-CD3- 
cells from TSP/HAM patients and HTLV-I car- 
rier. Results are expressed as in Fig. 1. 
Table  5.  Phenotypic Characterization of Induced and Spontaneous T  Cell Colonies from PBMC and E- CD3-  Cells of TSP/HAM 
Patients, HTLV-I Carrier, and HTLV-I-seronegative Controls 
Percent positive cells 
Induced colonies from 
PBMC 
Spontaneous colonies from 
PBMC  Spontaneous colonies from E-CD3- 
Patient  Tac  CD1  CD3  CD4  CD8  p19  Tac  CD1  CD3  CD4  CD8  p19  CD25(Tac)  CD1  CD3  CD4  CD8  p19 
2  27  28  76  62  25  21  30  31  78  67  23  28  37  30  76  61  21  37 
3  31  24  74  62  29  31  26  25  71  65  24  25 
4  22  32  78  65  21  21  29  27  78  60  21  18 
5  30  28  79  61  31  30  27  25  74  58  30  24  31  26  70  59  24  33 
9  31  32  82  73  28  24  24  30  80  72  24  15 
6  22  31  75  63  20  19  20  24  74  61  22  19 
11"  19  34  78  59  21  21  22  35  78  65  21  13  25  25  74  67  23  39 
-(n  =  3)*  36  3  80  62  37  0 
Individually picked colonies were 
ing mAb. 
* HTLV-I carrier. 
t HTLV-I-seronegative controls. 
pooled, washed, and dissociated, and colony cells were stained by indirect immunofluorescence  with the correspond- 
745  Lunardi-Iskandar et al. Figure 4.  Electron microscopy of HTLV-I viral particles 
from:  (A) spontaneous T  cell colony from  TSP/HAM pa- 
tient's PBMC,  and (B) spontaneous T cell colony from in- 
fected cord blood mononuclear cells after coculture for 3 d 
in liquid culture with T cell colonies  from TSP/HAM PBMC. 
The cord blood cells  were plated in the T-CFC assay, and spon- 
taneous colonies were examined by electron microscopy. (C) 
Same as in B, but after 9 d of liquid culture. 
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Patients, HTLV-I Carrier, and HTLV-I-seronegative Controls 
Patient 
Immediate plating  Delayed plating 
Spontaneous  Induced  Spontaneous  Induced 
4  45  +  5  332  _+  28  51  +  12  280  +  18 
5  57  _+  4  421  _+  23  49  +  6  300  +  24 
2  52  _+  7  298  +  12  67  +  9  285  +  20 
6  45  _+  7  380  _+  10  38  _+ 4  290  +  16 
11"  20 +  2  310  _+  12  28  _+  8  296  +  12 
(n  =  3)~  0  284  +  27  0  140  _+  29 
Cells (5  x  105/ml) were seeded in methylcellulose after 72 h of liquid 
culture in KPMI 1640 with 10% FCS in the absence of added growth 
factors or mitogens. Results are expressed  as mean number of colonies 
per 5  x  104 seeded cells from triplicate culture. 
*HTLV-I carrier. 
HTLV-I-seronegative controls. 
in the induced and spontaneous T cell colonies  from the PBMC 
of both the healthy HTLV-I carrier and the TSP/HAM pa- 
tient examined (Fig. 4). 
Clonogenic Capacity of T-CFC.  The proliferative capacity 
of PBMC T-CFC was also tested after incubating primary 
PBMC in liquid culture for 3-5 d, in the absence of added 
growth factors or mitogens, before seeding in methylcellu- 
lose. This delayed plating has been proposed  as a measure 
of the proliferative capacity of the clonogenic cells (9-13). 
As shown in Table 6, delayed plating of spontaneous and in- 
duced T-CFC from TSP/HAM patients  and asymptomatic 
carriers was similar to immediate plating. 
Infection of Normal T-CFC by Coculture.  HTLV-I  gag p19 
expression by the cells in the T  cell colonies indicates that 
at least a portion of them are infected by HTLV-I. To further 
confirm this, pooled T cell colonies from spontaneous or in- 
duced T-CFC were irradiated with 2,500 cGy, and cocultured 
with pooled T cell colonies of normal bone marrow T-CFC 
or with normal PHA-activated cord blood mononuclear cells. 
Virus replication was monitored by the expression of HTLV-I 
gag p19 and electron microscopy. Gag p19 antigen was de- 
tected at 3, 6, 9,  15, and 60 d of the liquid cocultures.  In 
addition, cells that were replated in methylcellulose 3, 6, and 
9 d after the start of coculture could generate spontaneous 
T cell colonies. Spontaneous T cell colonies, obtained  after 
3 and 9 d of liquid coculture, also showed HTLV-I particles 
by electron microscopy (Fig. 4). 
Discussion 
The initial intent of these investigations was to study quan- 
titatively  and qualitatively the peripheral blood T-CFC  of 
TSP/HAM patients and healthy HTLV-I-infected  individuals. 
It has previously been demonstrated (25-29) that an unusual 
spontaneous T lymphocyte  proliferation exists in TSP/HAM 
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patients and healthy HTLV-I carriers. This study allowed us 
to determine that the spontaneous T lymphocyte prolifera- 
tion also occurs at the level of the T-CFC, which is an indi- 
cator of the T cell progenitor population. Our results, as well 
as previous studies, demonstrate that there is an increased 
CD25 expression on PBL of  TSP/HAM patients and healthy 
HTLV-I carriers (25-31). This suggests that there is abnormal 
activation of T cells in vivo since CD25 is an epitope of the 
ID2K ot chain. The mechanism through which spontaneous 
T lymphocyte proliferation  and spontaneous T cell colony 
formation arise appears to occur at least partly through the 
interaction of Ib2 with its receptor. Spontaneous prolifera- 
tion of TSP/HAM T lymphocytes in liquid culture can be 
inhibited by  antibodies  directed  against  the  ID2K  (29). 
Moreover, an expression of IL-2 has been demonstrated in 
these cultures, strongly suggesting an autocrine IL-2/IL-2K 
loop in TSP/HAM. We have extended these observations to 
the level of the T-CFC, which in TSP/HAM and healthy car- 
riers not only show an abnormal spontaneous proliferation, 
but also an expression of the II~2R on the T cell colonies 
they generate. Furthermore, the spontaneous T cell colony 
formation of PBMC from HTLV-I-infected individuals  is 
strongly inhibited by antibodies directed against the IL-2K 
and fl chains. In contrast to the healthy HTLV-I-seronegative 
individuals, the results reported here indicate that T-CFC from 
all TSP/HAM patients  and healthy HTLV-I carriers exam- 
ined showed abnormal proliferative properties. These spon- 
taneously proliferating  T-CFC  of TSP/HAM patients  and 
HTLV-I carriers possessed great self-renewal capacity in the 
absence of added growth factors. Conversely, spontaneously 
proliferating T-CFC from HIV-l-infected individuals have lost 
their self renewal capacity, which is a property of primitive 
progenitor cells (9-13). 
To determine more precisely  the clonogenic capacity of  pre- 
sumably mature and immature T-CFC, various PBMC frac- 
tions, E + (CD2 +) ("mature" T lymphocytes) or E- (CD2-) 
CD3-  (immature T lymphocytes),  were tested for sponta- 
neous T cell colony growth with or without adherent cells. 
Spontaneous T  cell colonies originated from both mature 
(E +) and immature (E- CD3-) T-CFC. Preincubation with 
anti-CD3 mAb did not stimulate (or inhibit) the growth of 
spontaneous T cell colonies, originating from unfractionated 
PBMC,  E +,  or  E-CD3-  fractions.  Since the  anti-CD3 
mAb did not stimulate the growth of spontaneous colonies 
of specimens that were not depleted of mature T lympho- 
cytes, it is highly unlikely that the generation of T cell colo- 
nies from E- CD3- is due to a mitogenic effect of the anti- 
CD3  antibody on any residual T  cells. 
A-, A- E +, and E + cells from peripheral blood of HTLV- 
I-infected individuals generated significantly lower number 
of spontaneous  T  cell colonies  than  unfractionated cells, 
strongly suggesting  that the generation of spontaneous  T 
cell colonies from mature T-CFC requires cellular coopera- 
tion between T-CFC and adherent cells. We were not able 
to block the generation of spontaneous T  cell colonies by 
mAbs directed against MHC class I or class II molecules, 
suggesting that the interaction with adherent cells does not 
occur via a MHC class I- or II-restricted mechanism.  In- terestingly, only autologous but not ailogeneic adherent cells 
were able to restore spontaneous T colony formation in ad- 
herent cell-depleted PBMC.  It is unclear why autologous 
adherent cells from HTLV-I-infected individuals behave differ- 
ently from allogeneic adherent cells from healthy seronega- 
tire donors. It may be due to a higher level of activation of 
adherent ceils in HTLV-I-infected  individuals. 
In contrast, the removal of adherent ceils did not result m a 
decrease of the number of spontaneous T cell colonies from 
fractionated immature T  cells (A - E- CD3 -  vs  E - CD3 -), 
suggesting that cellular cooperation between adherent ceils 
and T-CFC is not necessary for the generation of spontaneous 
T cell colonies from immature T-CFC. The reason why im- 
mature T-CFC, as opposed to mature T-CFC, do not require 
cooperation with adherent ceils for spontaneous T cell colony 
formation is not dear, but could be due to a higher level of 
activation of immature T-CFC 
Surprisingly, when the T-CFC were cultured in the pres- 
ence of Ib2 without PHA or mitogens, the growth of spon- 
taneous T cell colonies was signrficantly inhibited ~  <0.0001), 
as compared with cultures without PHA or IL-2. We do not 
yet understand this phenomenon, but one possibility is that 
Ib2 stimulates suppressor T cells to produce factors inhibiting 
the proliferation of T-CFC. 
In TSP/HAM patients and healthy HTLV-I careers, pooled 
spontaneous and induced T cell colonies were composed of 
a high proportion of cells bearing the CD1 + surface pheno- 
type.  Conversely,  T  cell  colonies generated from healthy 
seronegative individuals displayed <4% CD1 + cells (9-13) 
The CD1 + antigen is characteristic  of immature T lympho- 
cytes (34-36), and its presence on cells of the T cell colonies 
may indicate a block of the in vitro differentiation of HTLV- 
I-infected cells. There appears to be a relationship between 
CD1 + expression  and HTLV-I infection since CD1 was ex- 
pressed  on the membrane of "~30%  of HTLV-I gag p19 + 
antigen-positive cells in both induced and spontaneous T cell 
colonies of TSP/HAM patient and HTLV-I carrier PBMC. 
This suggests that CD1 + immature T cells may be a target 
of HTLV-I. 
Direct evidence of the infecnon of T-CFC was shown by 
the capacity of pooled irradiated T cell colonies of TSP/HAM 
patients to transmit HTLV-I to normal cord blood or bone 
marrow mononuclear cells. Moreover, when these cocultured 
cells were replated in methylcellulose, we observed  sponta- 
neous growth of T-CFC from the infected bone marrow and 
cord blood cells. Recently, it was demonstrated that an early 
event in HTLV-I infection promotes the spontaneous growth 
of T-CFC (37). It is possible that HTLV-I triggers a molec- 
ular system(s)  necessary  for the proliferation of T-CFC. 
Three important conclusions can be drawn from this study. 
First, in contrast to PBMC from normal individuals, PBMC 
from HTLV-I-mfected individuals contain T cell progemtors 
with abnormal proliferative  properties, since they can grow 
in the absence of added growth factors (spontaneous T  cell 
colony formation).  Second,  T-CFC  from TSP/HAM  and 
HTLV-I carrier PBMC show abnormal differentiation in vitro, 
as evidenced by the CD1 + of part of the cells in the T  cell 
colonies. Third, T-CFC from HTLV-I-lnfected lndivaduals seem 
to be infected in vlvo, raising the possibility that the T-CFC 
may be the main target and an important reservoir for HTLV-I 
infection. One of the most remarkable findings of this study 
is the rapid appearance of HTLV-I-expressing  cells after cul- 
tivation in vatro. This is in contrast to previous reported studies, 
where liquid suspension cultures of HTLV-I-mfected ceils only 
led to a gradual and slow selection of cells expressing viral 
antigens (38)  Our interpretation is that culture in semisolid 
medium allows for the rapid selection of the target cell of 
infection by HTLV-I (HTLV-I-mfected T-CFC) from the rest 
of the cell population. 
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